Medical Xpress August 15, 2024
Elodie MAZEIN with Beiyi SEOW in Washington

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

Their statements came after US President Joe Biden and Vice President Kamala Harris announced a deal to lower costs of the first 10 drugs picked for Medicare price talks.

The agreement with drugmakers—who said they came on board with negotiations as they had no choice—is set to save seniors in the United States $1.5 billion in out-of-pocket costs.

It is the result of months of negotiations and is anticipated to save Medicare $6 billion in the first year alone, said Biden, referring to the federal health insurance for seniors.

While the announcement...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Lawmakers renew focus on PBMs: 4 things to know
How 4 top pharmacy leaders are leveraging AI for transformation
Health Economics and Outcomes Research: Biopharma’s Underappreciated Value Creator
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs
Private equity deal would set stage for 3-way Walgreens split: Report

Share This Article